Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04026789
Other study ID # 2019P000848
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 22, 2019
Est. completion date July 31, 2021

Study information

Verified date October 2020
Source Planned Parenthood League of Massachusetts
Contact Principal Investigator
Phone 6176161600
Email research@pplm.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare time to completed abortion between two protocols for patients seeking medication abortion - same-day start versus delay-for-diagnosis - in the setting of asymptomatic, low-risk, pregnancy of unknown location.


Recruitment information / eligibility

Status Recruiting
Enrollment 57
Est. completion date July 31, 2021
Est. primary completion date July 17, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Patients with an undesired pregnancy of less than or equal to 42 days gestation based on last menstrual period (LMP) who present to Planned Parenthood League of Massachusetts (PPLM)'s Greater Boston Health Center seeking medication abortion will be considered for study participation.

Inclusion criteria:

- Positive urine or serum hCG test

- No evidence of gestational sac on transvaginal ultrasound

- Desire for medication abortion as method of pregnancy termination

Exclusion criteria:

- Ineligible for medication abortion at PPLM based on current PPLM clinical guidelines

- Reasonable clinical suspicion for ectopic or molar pregnancy, such as abnormal or concerning ultrasound findings

- High risk for ectopic pregnancy, such as prior ectopic pregnancy, history of tubal surgery, concurrent intrauterine device in place during this pregnancy

- Exhibiting symptoms of possible ectopic, such as vaginal bleeding or abdominal pain

- LMP > 42 days or unknown LMP

- Age less than 18 years

- Prior participation in this study

- Anticipated inability to present for scheduled follow-up visits

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Same-day-start
Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to same-day start will have their medication abortion initiated on the day that they present for services while simultaneously ruling out ectopic pregnancy with serial hcg testing
Delay-for-diagnosis
Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to delay-for-diagnosis will first have ectopic pregnancy ruled out with serial hcg and ultrasounds prior to initiating medication abortion

Locations

Country Name City State
United States PPLM Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Planned Parenthood League of Massachusetts

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to completed abortion Time to completed abortion as defined by the number of days between initial ultrasound diagnosis of PUL to the diagnostic test that confirms complete abortion through study completion, an average of two weeks
Secondary Number of participants with complete expulsion of pregnancy without surgical intervention Efficacy of medical abortion, defined as number of participants with complete expulsion of pregnancy without surgical intervention 14 days after initiation of medical abortion
Secondary Time to diagnosis of pregnancy outcome Number of days between initial ultrasound diagnosis of pregnancy of unknown location and diagnosis of pregnancy outcome, with options including intrauterine pregnancy, ectopic pregnancy, or early pregnancy loss Within 2 weeks of identification of pregnancy of unknown location on ultrasound
Secondary Rate of ectopic pregnancy Rate of ectopic pregnancy among entire study population Within 2 weeks of identification of pregnancy of unknown location on ultrasound
Secondary Percent of participants who complete follow-up and confirm complete abortion Percent of participants who adhered to recommended follow-up plan and confirmed a complete abortion through ultrasound or hCG Within 1 month of identification of pregnancy of unknown location on ultrasound
See also
  Status Clinical Trial Phase
Completed NCT05017974 - Research on Improving Sleep During Pregnancy N/A
Completed NCT03284515 - Vaccination In Pregnancy Gene Signature: VIP Signature Study
Recruiting NCT05969795 - Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support Phase 1
Recruiting NCT06051201 - Innovation for Small-scale Experiments: ReceptIVFity Test N/A
Recruiting NCT04828382 - Prospective Study of Pregnancy in Women With Cystic Fibrosis
Enrolling by invitation NCT04527926 - STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy N/A
Recruiting NCT04278651 - Early Antenatal Support for Iron Deficiency Anemia Phase 4
Recruiting NCT04405700 - Measuring Adverse Pregnancy and Newborn Congenital Outcomes
Recruiting NCT06258902 - Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
Completed NCT05487196 - Effectiveness of Clonidine, Dexmedetomidine, and Fentanyl Adjuncts for Labor Epidural Analgesia Phase 2
Completed NCT03750968 - Lutein & Zeaxanthin in Pregnancy - Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects Phase 2
Enrolling by invitation NCT06127277 - Next4You: A Fully Mobile Relationships Based Program for Youth in Foster Care N/A
Completed NCT05897697 - Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
Recruiting NCT05899101 - The Impact of Opioid and Cannabis Exposure on Fetal Growth
Completed NCT05502510 - Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
Completed NCT04296396 - Opioid Prescription After Cesarean Trial Phase 3
Not yet recruiting NCT06069869 - Multiple Micronutrient Supplementation (MMS) Iron Dose Acceptability Crossover Trial Phase 3
Not yet recruiting NCT06069856 - Multiple Micronutrient Supplementation (MMS) IFA- Iron Dose Acceptability Crossover Trial Phase 3
Not yet recruiting NCT06079918 - Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania Phase 3
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A